About IntraBiotics Pharmaceuticals
IntraBiotics Pharmaceuticals is a company based in Mountain View (United States) founded in 1994. IntraBiotics Pharmaceuticals has raised $40.4 million across 3 funding rounds from investors including Orbimed, International Bio Medical and New England Capital Partners. IntraBiotics Pharmaceuticals operates in a competitive market with competitors including AFYX Therapeutics, OraPharma, Marizyme, Acologix and AB-Biotics, among others.
- Headquarter Mountain View, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$40.4 M (USD)
in 3 rounds
-
Latest Funding Round
$3.5 M (USD), Series B
Mar 01, 2003
-
Investors
Orbimed
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of IntraBiotics Pharmaceuticals
IntraBiotics Pharmaceuticals has successfully raised a total of $40.4M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $3.5 million completed in March 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IntraBiotics Pharmaceuticals
IntraBiotics Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, International Bio Medical and New England Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
A private investment firm focused on acquiring operating companies.
|
Locked | Locked | Locked | |
|
Portfolio of medical devices
|
Locked | Locked | Locked |
Investor details for IntraBiotics Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IntraBiotics Pharmaceuticals
Investment portfolio details for IntraBiotics Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IntraBiotics Pharmaceuticals
Detailed financials for IntraBiotics Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intrabiotics Pharmaceuticals Comparisons
Peer comparison for IntraBiotics Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IntraBiotics Pharmaceuticals
IntraBiotics Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AFYX Therapeutics, OraPharma, Marizyme, Acologix and AB-Biotics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug patches for mucosal disease treatments are developed.
|
|
| Locked | Locked | Locked |
Oral health products for treatment and maintenance are developed.
|
|
| Locked | Locked | Locked |
Therapies for chronic wounds, thrombolysis, and dental health are developed.
|
|
| Locked | Locked | Locked |
Therapeutics are developed for kidney and bone metabolic disorders.
|
|
| Locked | Locked | Locked |
Probiotic drugs for dental disorders and nutraceuticals are developed.
|
Detailed competitors of IntraBiotics Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intrabiotics Pharmaceuticals
Complete news archive for IntraBiotics Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IntraBiotics Pharmaceuticals
IntraBiotics Pharmaceuticals was founded in 1994 and raised its 1st funding round 5 years after it was founded.
IntraBiotics Pharmaceuticals is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
IntraBiotics Pharmaceuticals is a funded company, having raised a total of $40.4M across 3 funding rounds to date.
IntraBiotics Pharmaceuticals was established in 1994 in Mountain View, United States, within the pharmaceuticals sector. Focus is placed on developing antibiotics to address oral mucositis in patients receiving radiotherapy for head-and-neck malignancies. The lead product, iseganan HCl, a synthetic peptide exhibiting broad-spectrum antimicrobial properties, is undergoing a pivotal Phase III clinical trial. Operations center on advancing treatments for radiotherapy-related complications.
IntraBiotics Pharmaceuticals's top competitors include Marizyme, AFYX Therapeutics and AB-Biotics.
IntraBiotics Pharmaceuticals has 4 investors. Key investors include Orbimed, International Bio Medical, New England Capital Partners, and Kauffman Foundation.